



Thursday August 9, 2001 9:31 am Eastern Time

**Press Release**

*SOURCE: diaDexus, Inc.*

**diaDexus and Fujirebio Announce Collaboration for Development And Commercialization of Novel Cancer Tests**

SANTA CLARA, Calif., Aug. 9 /PRNewswire/ -- diaDexus, Inc. announced today that it has entered into a research and license collaboration agreement with Fujirebio, Inc. to develop and sell cancer diagnostic tests in Japan.

Under the terms of the agreement, diaDexus will receive licensing fees and funding from Fujirebio to support further research and development efforts for three years. In addition, diaDexus will receive royalty payments on future sales. Fujirebio has been granted exclusive commercialization rights in Japan for any resulting cancer diagnostic products. Fujirebio also purchased diaDexus Series D preferred shares.

"We are delighted to partner exclusively with Fujirebio," said Patrick Plewman, chief executive officer of diaDexus. "Fujirebio is a market leader in cancer diagnostics in Japan, and has a history of embracing cutting edge technologies. This makes them the ideal commercialization partner for us in Japan. Furthermore, this provides the first commercial validation of our discovery model and the royalty rates reflect the value of proprietary diagnostic tests."

"We are constantly assessing new technologies for potential commercial application in our own business model," said Tatsuo Tokumitsu, president and chief executive officer of Fujirebio. "We feel that diaDexus molecular diagnostic discovery program will produce exciting cancer tests which will provide Japanese physicians with unique, important patient identification and management information."

**ABOUT FUJIREBIO**

Fujirebio, located in Tokyo, Japan, specializes in clinical diagnostic reagent products, based on its immunological technologies. Fujirebio is the largest domestic clinical diagnostic company in Japan. Fujirebio owns a significant share of SRL, the largest clinical reference laboratory in Japan, and also has a collaboration with ZYOMYX, of Hayward California. Additional information about Fujirebio can be obtained at <http://www.fujirebio.co.jp>.

**ABOUT DIADEXUS**

diaDexus, located in Santa Clara, California, is focused on translating genomic sequence data into novel diagnostic and therapeutic products. diaDexus has utilized genomics and bioinformatics to identify thousands of disease-associated molecular targets. Currently diaDexus has two diagnostic product candidates in late-stage pre-clinical development.

For more information, please visit the diaDexus Web site at [www.diadexus.com](http://www.diadexus.com).

*SOURCE: diaDexus, Inc.*